EZH2 and prostate carcinoma: It remains an interesting question for future investigation regarding how the EZH2-REST relationship evolves during prostate cancer progression, from REST being an EZH2 partner in prostate adenocarcinoma cells to REST becoming an EZH2 target in NEPC cells.